Pharma Update

Trontinemab: First Aß-targeting Ab brain shuttle technology Best-in-disease potential: Fast and highly efficient plaque removal after 3-6 months Trontinemab (Brain Shuttle TfR1-binding IgG) Ongoing Ph I/II dose finding study in AD Staggered, parallel-group design, with 4 initial sequential cohorts Blood BBB Brain tissue Transferrin receptor 1 Gantenerumab binder Brain shuttle module Aggregated Aẞ طع Screening up to 12 weeks Cohort 4 Cohort 3 Cohort 2 Cohort 1 Parallel-group, double-blind treatment period D1 Start of treatment 28 weeks W28 primary endpoint Follow-up 28 weeks • • Trontinemab, brain shuttle, is an antibody format composed of gantenerumab and a linked transferrin receptor (TfR1) binding moiety The construct can achieve efficient transport over the blood brain barrier and target Aẞ plaque in the brain¹ • Ongoing Ph I/II study investigating four patient cohors (10-15 patients per cohort) with prodromal or mild-to-moderate AD for 7 months and with an option to expand most promising cohorts • Faster and more efficient plaque removal, could result in a more pronounced delay in disease progression compared to first generation anti-amyloid therapies • Updated data from the ongoing Ph I/II study to be presented at CTAD 2023 on Oct 24-27th 1 Gantenerumab brain shuttle results were compared with historical data obtained from a previous gantenerumab SAD trial (BN18726; 2.Kulic L. et al., ADPD 2021); AD=Alzheimer's disease; TfR1-Transferrin receptor protein 1; IgG-Immuno-globulin G; BBB-blood brain barrier; mAb-monoclonal antibody; Aẞ-Amyloid ẞ; Ab=Antibody Roche 109

View entire presentation